Joule Receives Prestigious Frost & Sullivan Technology Innovation Award

Joule Receives Prestigious Frost & Sullivan Technology Innovation Award

March 2, 2015

Bedford, Mass. – Joule, the pioneer of direct, solar recycling of CO2-to-liquid fuels, announced today that its platform was awarded the 2015 Technology Innovation Award by Frost & Sullivan. The award, which recognizes organizations addressing unique and critical challenges, was presented to Joule for its ability to recycle waste carbon dioxide (CO2) into drop-in liquid fuels using sunlight.

FDA Advisory Committee Recommends Approval for Avedro’s Riboflavin Ophthalmic Solutions with UVA Irradiation for Corneal Collagen Cross-Linking to Treat Progressive Keratoconus and Corneal Ectasia

FDA Advisory Committee Recommends Approval for Avedro’s Riboflavin Ophthalmic Solutions with UVA Irradiation for Corneal Collagen Cross-Linking to Treat Progressive Keratoconus and Corneal Ectasia

February 27, 2015

Avedro, Inc., a Boston-based ophthalmic pharmaceutical and medical device company, announced today that on February 24, 2015 the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee and Ophthalmic Devices Panel of the Medical Devices Advisory Committee voted in support of approval for Avedro’s new drug application (NDA) for riboflavin ophthalmic solutions with UVA irradiation for use in corneal collagen cross-linking for the treatment of the conditions underlying progressive keratoconus or corneal ectasia following refractive surgery.

Concert Pharmaceuticals Reports Year End 2014 Financial Results

Concert Pharmaceuticals Reports Year End 2014 Financial Results

February 27, 2015

Conference Call Scheduled Today at 8:30 a.m. ET

Joule Is Poised For Significant Progress in 2015

Joule Is Poised For Significant Progress in 2015

February 23, 2015

Reaches major milestones in 2014 to enable broad industrialization of its carbon-neutral transportation fuels

Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results

Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results

February 17, 2015

Positive early clinical results in three distinct investigational medicines and a strong financial position support advancement of the Agios portfolio into late stage development

Avedro Announces Date for FDA Advisory Committee Meeting

Avedro Announces Date for FDA Advisory Committee Meeting

February 17, 2015

Committee to Review Avedro’s NDA for Riboflavin Ophthalmic Solutions with UVA Irradiation on February 24, 2015

Syros Pharmaceuticals Presents New Data on Use of its Gene Control Platform for Predicting Drug Response

Syros Pharmaceuticals Presents New Data on Use of its Gene Control Platform for Predicting Drug Response

February 10, 2015

- Abstract at AACR Translation of the Cancer Genome meeting describes novel approach to discovery of gene control biomarkers -

Concert Pharmaceuticals Announces Appointment of James V. Cassella as Chief Development Officer

Concert Pharmaceuticals Announces Appointment of James V. Cassella as Chief Development Officer

February 4, 2015

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has appointed James V. Cassella, Ph.D. as Chief Development Officer. In this newly created role, Dr. Cassella will lead Concert's product development strategy and operations and will have responsibility for all preclinical, clinical and manufacturing activities.

T2 Biosystems and Canon U.S. Life Sciences Announce Joint Collaboration to Develop Novel Test Panel to Rapidly Detect Lyme Disease

T2 Biosystems and Canon U.S. Life Sciences Announce Joint Collaboration to Develop Novel Test Panel to Rapidly Detect Lyme Disease

February 3, 2015

Collaboration Leverages T2 Biosystems' Proprietary T2MR(R) Technology and Canon's Collective Expertise to Enable Improved Diagnostics

Symbiota Names Global Crop Protection Expert Peter Innes, Ph.D. to Board of Directors

Symbiota Names Global Crop Protection Expert Peter Innes, Ph.D. to Board of Directors

February 3, 2015

CAMBRIDGE, Mass., Feb. 3, 2015 /PRNewswire/ -- Symbiota™, pioneer of plant microbiome solutions that naturally promote crop health and improve agricultural production, today announced the addition of Peter Innes, Ph.D. to its board of directors.